Karyopharm Therapeutics (KPTI) Cost of Revenue (2019 - 2026)
Karyopharm Therapeutics (KPTI) recorded Cost of Revenue of $1.09 million in Q2 2026, up 3.2% from $1.05 million a year earlier.
Powered by 
Analysis
Karyopharm Therapeutics (KPTI) Cost of Revenue (2019 - 2026) Analysis & Trends
On a TTM basis, Karyopharm Therapeutics' Cost of Revenue came in at $5.73 million as of Jun 30, 2026, up 15.1% year-over-year; for FY2025, it was $5.95 million, down 1.0% from FY2024.
- Annual Cost of Revenue has a five-year compound annual growth rate of 17.1% (FY2020 to FY2025).
- Across earlier years, Cost of Revenue came in at $6.01 million in FY2024 (+21.5%), $4.94 million in FY2023 (-5.2%), $5.21 million in FY2022 (+53.2%) and $3.4 million in FY2021 (+25.8%).
- Quarterly Cost of Revenue has ranged from $589,000 in Q3 2021 to $2.11 million in Q3 2025 over the past five years.
- On a year-over-year basis, Cost of Revenue rose in four of the last seven quarters, with growth averaging 7.1%.
- Peak year-over-year performance for Cost of Revenue in the last five years was growth of 151.8% in Q4 2022, against a decline of 31.9% in Q1 2025 at the low end.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | 3.27 Bn |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | 8.05 Bn |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | 4.29 Bn |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | 4.40 Bn |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | 3.71 Bn |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | 2.52 Bn |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | 2.81 Bn |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | 1.58 Bn |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | 4.09 Bn |
| 10 | Karyopharm Therapeutics | 23.15 Mn | -203.27 Mn | 32.35 Mn | 1.09 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.09 Mn |
| Dec 31, 2025 | 1.48 Mn |
| Sep 30, 2025 | 2.11 Mn |
| Jun 30, 2025 | 1.05 Mn |
| Mar 31, 2025 | 1.30 Mn |
| Dec 31, 2024 | 1.33 Mn |
| Sep 30, 2024 | 1.30 Mn |
| Jun 30, 2024 | 1.47 Mn |
| Mar 31, 2024 | 1.91 Mn |
| Dec 31, 2023 | 1.49 Mn |
| Sep 30, 2023 | 911,000.00 |
| Jun 30, 2023 | 1.19 Mn |
| Mar 31, 2023 | 1.35 Mn |
| Dec 31, 2022 | 1.87 Mn |
| Sep 30, 2022 | 980,000.00 |
| Jun 30, 2022 | 939,000.00 |
| Mar 31, 2022 | 1.43 Mn |
| Dec 31, 2021 | 742,000.00 |
| Sep 30, 2021 | 589,000.00 |
| Jun 30, 2021 | 1.14 Mn |
API Access
Karyopharm Therapeutics Cost of Revenue API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=cost-of-revenue&ticker=KPTI&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "cost-of-revenue", "ticker": "KPTI", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=cost-of-revenue&ticker=KPTI&period=max&api_key=YOUR_API_KEY");
const data = await res.json();